Jazz Buys Actio Biosciences in $1.3B Rare Epilepsy Deal

Eight hundred and twenty million dollars, in cash, at signing — for a drug aimed at a disease that affects people in the United States. Jazz just made that trade.

And while that was landing, a cystic fibrosis biotech lost most of its market value before lunch, the FDA sent a radiopharmaceutical back over its factories, and the White House came for the MMR schedule. Busy Monday. Let's get into it.

Welcome to The Pharma Closeout for Monday, August 10th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Start with the eight-twenty, because everything else in this deal hangs off it. Jazz Pharmaceuticals is buying Actio Biosciences — private, San Diego — for $820 million up front, with up to $500 million more tied to regulatory and sales milestones. Total potential, just over $1.3 billion. What that money buys is one drug: ABS-1230, for epilepsy caused by mutations in a gene known as KCNT1.

In the U.S. — that's Jazz's own estimate. And I'd argue the strategic logic is tighter than that number makes it look. Jazz's neuroscience business already runs on Xywav and Epidiolex, it just posted what it calls its largest ever quarterly revenue at $1.2 billion, and the CEO's framing was deepening leadership in rare and severe epilepsies. This is a franchise buying the thing sitting directly next to it.

Then let me complicate the asset, because the disease is not the soft part of this story — the evidence is. In the severe end of this population, patients have dozens, sometimes hundreds of seizures a day, drug-resistant, with developmental consequences that compound. What Jazz and Actio have said publicly is that the drug produced "meaningful seizure reductions" in a proof-of-concept trial. That's the whole characterization. No number, no responder definition. And in a seizure population with that much day-to-day variability, whether you set the responder threshold at fifty percent reduction or ninety percent isn't a statistics footnote. It's the label.

And the trial that has to carry it is running now, and the companies say it could be the foundation for a U.S. approval application.

Fifty-five, with no approved comparator to anchor against.

Which is why the street hasn't credited it. TD Cowen's Joseph Thome told clients the deal adds meaningful pipeline optionality, but his team wants patient-level data, a readout timeline, and clarity on the regulatory package before assigning material value.

And I'd stop on the word optionality, because it's doing a lot of hiding. There's no approved therapy in this disease. That means no agreed efficacy standard, no precedent endpoint, no benchmark the agency has already blessed. Jazz didn't buy a de-risked asset with an execution question attached to it. Jazz bought a regulatory negotiation, and it paid the majority of the price before the negotiation starts.

I'll concede the timing point. I won't concede the logic. First-in-class mechanisms are exactly where you pay early — because the day the path is paved, the asset isn't private and it isn't $820 million. And Actio has said there's opportunity to test this in more prevalent genetic epilepsies.

Then say that out loud, because it reframes the whole deal. This isn't rare-disease M&A. Jazz is paying a first-in-class premium for a channel mechanism, entering through the smallest indication, with the broader genetic epilepsy population as the actual thesis. The 2,500 patients are the door. They're not the room.

That's the sharper read, and it's the one I'd carry into a portfolio review. Let's bring in Marcus Webb on the structure.

And there's a piece of this that doesn't close cleanly. At closing, Actio spins out a separate private entity, funded by existing investors, built around an early-stage ion channel inhibitor in Charcot-Marie-Tooth disease. Jazz takes a minority stake. So the program Jazz declined to underwrite still sits on its cap table.

Competitive read: if you run business development in rare neurology, the price of a private, pre-pivotal, first-in-class asset was just marked — above the market's median, with most of it paid at signing. Assume the next company you approach has already seen that print.

The other thing that repriced today repriced in the opposite direction.

By ninety-two percent. Sionna Therapeutics fell nearly that far in early trading, which leaves the company worth less than the $268 million in cash and equivalents it reported at the end of June.

Below cash. That's a wind-down price.

And the miss is unusually clean. Sionna tested its experimental drug SION-719 layered on top of Trikafta, against Trikafta alone, on sweat chloride. Sionna's own leadership had said ten millimoles per liter would be clinically meaningful and differentiating. The placebo-adjusted result came in at one, and it wasn't statistically significant. No additive effect from the combination means the most credible near-term competitive threat to Vertex Pharmaceuticals' dominant cystic fibrosis franchise is gone — Vertex traded up seven percent, and RBC's Brian Abrahams called it a clearing event.

A franchise projected at $13 billion this year, and the list of challengers keeps getting shorter.

What bothers me is the shape of the failure, not the size. Stifel's Paul Matteis said the data are hard to explain and leave his team puzzled. When the sell side can't build a mechanism for why a drug did nothing, nobody can price the next attempt at that combination either.

So the damage isn't confined to one balance sheet — it's a discount on everybody's CFTR combination thesis. Is there anything left in the building?

Sionna isn't zero. But management's language was preserving capital while evaluating next steps, and that is not the vocabulary of a company funding two programs.

Different kind of capital decision — Bristol Myers Squibb picked Houston for a new manufacturing campus. Approximately $2.3 billion, inside the company's stated $40 billion, five-year U.S. commitment. Modular and multi-modal by design: small molecules, biologics, antibody-drug conjugates, reconfigurable as the pipeline shifts.

The modularity is a confession, and I mean that admiringly. You build reconfigurable capacity when you genuinely don't know which modality you'll need in 2032.

Fair — though I'd read the flexibility as the point rather than the hedge.

Either way the implication for anyone modeling this is the same: onshoring capital lands in the cost base years before it lands in supply. Read this campus, and the ones that follow it, as a margin commitment first and a capacity announcement second.

On the regulatory side, the most instructive letter of the day had nothing to do with efficacy. ITM Isotope Technologies Munich received a complete response letter on August 7th for 177-lutetium edotreotide, ITM-11, in gastroenteropancreatic neuroendocrine tumors. The agency cited chemistry, manufacturing and controls items, plus third-party commercial facility inspection findings. No concerns on the clinical or nonclinical package. No safety issues. No additional data requested.

So the science passed and the plant didn't.

Which is the entire story for this modality. The pivotal COMPETE trial met its primary endpoint, with a statistically significant progression-free survival improvement against everolimus, and ITM says that package stands and it intends to resubmit. But radiopharmaceuticals are the one class where the manufacturing network is inseparable from the product. Short-lived isotopes, distributed fill sites, third-party facilities you don't own and can't fully control.

And a competitor can't out-engineer that with a better data cut.

No. Which is why every developer in this space should read this letter as a map of where the agency is currently spending its inspection attention.

Also worth noting on the regulatory front, the counterexample landed the same day. Scholar Rock removed Catalent Indiana — now part of Novo Nordisk — from the apitegromab biologics license application after that site received an Official Action Indicated classification following an April FDA inspection. Review continues exclusively through a second U.S. fill-finish facility, and the September 30th action date still holds.

Both sites were in the filing from day one.

That's the whole lesson, and it's cheaper than it sounds. The same category of manufacturing risk that just produced a complete response letter for ITM produced zero delay for Scholar Rock's SMA biologic — because the redundancy was written into the submission instead of negotiated after the inspection. For any biologic approaching filing, dual fill-finish is the least expensive regulatory insurance on the market.

One more, and it's a different kind of risk. Trump signed an executive order Monday recommending the MMR vaccine be split into three separate shots given at separate visits, and asserting a link to autism — a claim discredited across dozens of studies involving millions of people. It lands with the CDC reporting 2,465 confirmed measles cases as of August 6th, and the American Academy of Pediatrics estimating it would take a decade to develop three separate vaccines. Senator Bill Cassidy, a physician, called the order wrong.

The order asks agencies for reports and doesn't change access by itself. But CDC recommendations are what insurance coverage tracks. If you're modeling pediatric vaccine demand, the variable to watch isn't the order — it's the first coverage decision that starts following it.

Looking ahead — Jazz and Actio expect to close in the final three months of the year, with the Charcot-Marie-Tooth spinout forming at the same time. Apitegromab's September 30th date survived today intact. And ITM has a resubmission to scope.

Mine is narrower than any of those. Patient-level data on ABS-1230, and a timeline for that study. Whether one small trial can carry a filing in a disease with no approved therapy is the only question that tells you what Jazz actually bought.

And if that answer comes back yes, every private rare-neurology asset reprices again — before anyone has seen a pivotal readout.

The one I'll be sitting with tonight is the ITM letter. A trial that beat everolimus on progression-free survival, and what stands between it and patients is a facility inspection. That's a fixable problem, which somehow makes it worse. Have a good evening, everyone.

And that is your Pharma Closeout for Monday, August 10th — Jazz betting $820 million on a mechanism before the endpoint exists, Sionna falling below cash and handing Vertex the field, ITM's letter, and Scholar Rock's second fill-finish site quietly earning its keep. Follow the show on Spotify, Apple Podcasts, or wherever you listen — tomorrow's briefing lands on its own.